The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment ...The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.展开更多
Correction to:Translational Neurodegeneration(2022)11:24 https://doi.org/10.1186/s40035-022-00299-w Following publication of the original article[1],the authors identified some errors in the Additional files 1-5.The o...Correction to:Translational Neurodegeneration(2022)11:24 https://doi.org/10.1186/s40035-022-00299-w Following publication of the original article[1],the authors identified some errors in the Additional files 1-5.The original article[1]has been corrected.展开更多
基金the NIHR Newcastle Biomedical Research Centre based at Newcastle Upon Tyne Hospitals NHS Foundation Trust and Newcastle University.SJGL is supported by a National Health and Medical Research Council Leadership Fellowship(1195830).
文摘The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.
文摘Correction to:Translational Neurodegeneration(2022)11:24 https://doi.org/10.1186/s40035-022-00299-w Following publication of the original article[1],the authors identified some errors in the Additional files 1-5.The original article[1]has been corrected.
